G. Elliott Cook, PharmD, BCPS — —2006-07

G. Elliott Cook , PharmD, BCPS

Pharmacist
Provider Resources, Inc.
Assistant Professor, Lake Erie College of Osteopathic Medicine (LECOM) School of Pharmacy - 2007-2011
Phone: 814.860.5113
Email: ecook@lecom.edu

Biographical Sketch

Elliott received a Pharm.D. from Lake Erie College of Osteopathic Medicine School of Pharmacy and completed a PGY1 Pharmacy Residency at Hillcrest Hospital – a Cleveland Clinic Hospital. Currently, Elliott is the Chief Pharmacist at Provider Resources, Inc. (PRI) where he provides support and oversight to two national contracts for the Centers for Medicare and Medicaid Services (CMS).Through these contracts, Elliott and his colleagues at PRI generate savings for the Medicare Trust Fund through the Medicare Secondary Payer Program and the Medicare Part D Benefit. Additionally, Elliott constructs technical, business, and drug policy solutions for PRI and the federal government on multiple levels. Elliott has prior experience in hospital pharmacy, academics, and drug information. He has publications in major medical and pharmacy journals and has given presentations at both local and national pharmacy meetings. Elliott is board certified in Pharmacotherapy by the Board of Pharmaceutical Specialties and is licensed to practice pharmacy in both Pennsylvania and Ohio. Elliott is also a member of several professional pharmacy organizations and is currently the Northwest Regional Director for the Pennsylvania Pharmacists Association (PPA) which includes 14 counties. He currently sits on PPA’s board which is considered the leading voice for pharmacy within the Commonwealth.

Education

  • Georgetown University, Masters of Science – Clinical and Translational Research – Regulatory Science Concentration, 2014-2016
  • Hillcrest Hospital PGY1 Pharmacy Residency, Mayfield Heights, OH.
  • Lake Erie College of Osteopathic Medicine School of Pharmacy, Erie, PA
    • Doctor of Pharmacy
  • Pennsylvania State University at Erie, The Behrend College, Erie PA.
    • Pre-Pharmacy Coursework

Honors and Awards

  • 2016-2017, Georgetown Center of Excellence in Regulatory Science and Innovation Scholar ($5,000)

Publications

  • In press: Madden MM, Cook GE. Dietary supplementation in children and adolescents: supplementing with the ‘correct’ amount. JAMA Pediatr 2013.
  • Cook GE, Madden MM. The significance of information posted on the U.S. Food and Drug Administration’s website. J Manag Care Pharm 2013;19(1):72-3.
  • Cook GE, Powers AL. In reply: Potential safety signals and their significance. Arch Intern Med 2012;172(9):747-8.
  • Powers AL, Cook GE. Potential safety signals and their significance. Arch Intern Med 2012;172(1):72-73.
  • Cook GE. Missing published and unpublished data in guidelines. BMJ 2010; 340:c1337.
  • Cook GE, Sukkari SR, Sasich LD. An additional source of bias in antidepressant and other trials. Pharmacotherapy 2010; 30(3):117e-8e.
  • Cook GE, Sasich LD, Sukkari SR. FDA drug information that never reaches clinicians. N Engl J Med 2010; 11(6):561-3.
  • Cook GE, Sasich LD, Sukkari SR. DIONYSOS study comparing dronedarone with amiodarone. BMJ 2010; 240:c285.
  • Sasich LD, Sukkari SR, Cook GE, Tuttle DA. The importance of FDA approval packages and briefing documents in pharmacy education. Am J Pharm Educ 2009; 73(7) Article 126.
  • Kahaleh A, Cook GE. Pharmacy students providing patient medication discharge counseling in Pennsylvania. US Pharm 2009; 34(8):49-57.
  • Minor PD, Cook GE. Student pharmacists: don’t forget the product labeling. J Am Pharm Assoc 2008 Nov-Dec; 48(6):696,700.

Poster Presentations

  • In press - Cook GE, Fernandez SJ, Wilhelm EE, Stoto MA. The Impact of FDA Drug Safety Communications on Zolpidem Prescribing in a Large Health System. Academy Health’s Concordium 2016. September 2016.
  • Cook GE, Fernandez SJ, Wilhelm EE. Measuring the Impact of FDA Communication Alerts and Re-Alerts – The Citalopram Pilot. Academy Health’s Concordium 2015. September 2015.

Invited Lectures

  • Measuring the Impact of FDA Communication Alerts and Re-Alerts – The Citalopram Pilot. U.S. Food and Drug Administration. White Oak Campus. 2/16/2016.